Atossa Therapeutics receives FDA approval for metastatic breast cancer study.

Atossa Therapeutics has received a "Study May Proceed" letter from the FDA for its study in metastatic breast cancer using (Z)-endoxifen. The letter marks a regulatory milestone for the company and could potentially expand the use of (Z)-endoxifen for treating metastatic ER+/HER2- breast cancer. Dr. Steven Quay, Atossa's President and CEO, believes the drug's activity in resistant tumors and oncogenic signaling pathway may offer a new treatment tool.